Search hospitals > California > San Francisco
Kaiser Permanente San Francisco
Claim this profileSan Francisco, California 94115
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for HIV Infection
Conducts research for Human Immunodeficiency Virus Infection
Conducts research for Breast cancer
262 reported clinical trials
24 medical researchers
Summary
Kaiser Permanente San Francisco is a medical facility located in San Francisco, California. This center is recognized for care of Breast Cancer, Lung Cancer, HIV Infection, Human Immunodeficiency Virus Infection, Breast cancer and other specialties. Kaiser Permanente San Francisco is involved with conducting 262 clinical trials across 405 conditions. There are 24 research doctors associated with this hospital, such as Jennifer M. Suga, Tatjana Kolevska, MD, Samantha A. Seaward, and Andrew Rassi, MD.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Jennifer M. SugaKaiser Permanente-Oakland2 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
103 drugs studied
Tatjana Kolevska, MDKaiser Permanente-Vallejo2 years of reported clinical research
Studies Cancer
Studies Melanoma
22 reported clinical trials
52 drugs studied
Samantha A. SeawardKaiser Permanente Medical Center - Santa Clara3 years of reported clinical research
Studies Breast Cancer
Studies Prostate Cancer
22 reported clinical trials
63 drugs studied
Andrew Rassi, MDKaiser Permanente San Francisco7 years of reported clinical research
Studies Tricuspid Regurgitation
Studies Tricuspid Valve Regurgitation
7 reported clinical trials
11 drugs studied
Clinical Trials running at Kaiser Permanente San Francisco
Lung Cancer
Ovarian Cancer
Breast Cancer
Cancer
Esophageal cancer
Non-Small Cell Lung Cancer
Breast cancer
Prostate Cancer
Cutaneous Melanoma
Melanoma
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Kaiser Permanente San Francisco?
Kaiser Permanente San Francisco is a medical facility located in San Francisco, California. This center is recognized for care of Breast Cancer, Lung Cancer, HIV Infection, Human Immunodeficiency Virus Infection, Breast cancer and other specialties. Kaiser Permanente San Francisco is involved with conducting 262 clinical trials across 405 conditions. There are 24 research doctors associated with this hospital, such as Jennifer M. Suga, Tatjana Kolevska, MD, Samantha A. Seaward, and Andrew Rassi, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.